文献速递治疗药物监测与药物基因组学药物相互作用

来那卡帕韦与扑米酮联用启动治疗:治疗药物监测病例报告

Lenacapavir initiation with concomitant primidone: A case report with therapeutic drug monitoring.
PubMed 文献 · Br J Clin Pharmacol · 2026-10-06

本文报道一例67岁男性在长期服用扑米酮50 mg/日的情况下启动来那卡帕韦(LEN)治疗,并在首个6个月给药间期内进行血浆药物浓度监测。结果显示LEN浓度始终高于蛋白校正95%有效浓度的四倍,最低为第1个月24.9 ng/mL,最高为第3个月58.3 ng/mL,预测6个月浓度为40.6 ng/mL,病毒载量持续检测不到。提示LEN与扑米酮联用可能具有药代动力学合理性。

要点

  • LEN与扑米酮联用虽不推荐,但本例监测浓度仍高于有效阈值四倍。
  • 第1个月LEN浓度最低为24.9 ng/mL,第3个月最高为58.3 ng/mL。
  • 预测6个月浓度为40.6 ng/mL,病毒载量持续检测不到。

核心结论

  • 本例为LEN与扑米酮联用提供了药代动力学依据,可能有助于未来临床决策。

研究设计与样本

  • 病例报告:67岁男性,从含增强剂达芦那韦方案转换后启动LEN,同时长期服用扑米酮50 mg/日。
  • 在首个6个月给药间期内采集血样,采用验证的液相色谱-串联质谱法测定血浆LEN浓度。

主要发现

  • LEN浓度在监测时间点均高于蛋白校正95%有效浓度的四倍。
  • 最低观察浓度为第1个月24.9 ng/mL,最高为第3个月58.3 ng/mL。
  • 预测6个月浓度为40.6 ng/mL,与无显著药物相互作用既往研究报道的浓度基本一致。
  • 给药间期内及后续给药后病毒载量均检测不到。

关键数值与推荐

  • LEN浓度高于蛋白校正95%有效浓度的四倍。
  • 最低观察浓度24.9 ng/mL(第1个月),最高58.3 ng/mL(第3个月),预测6个月浓度40.6 ng/mL。

临床怎么用

  • 对于需联用扑米酮的患者,启动LEN时可考虑进行治疗药物监测以评估浓度。
  • 监测结果可辅助判断LEN与扑米酮联用时的暴露水平是否足够。

局限性

  • 为单例病例报告,结果不能推广至所有联用扑米酮的患者。
  • LEN与扑米酮联用时浓度下降的程度仍未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lenacapavir (LEN), a first-in-class capsid inhibitor, has unique pharmacokinetics that enable twice-yearly dosing. LEN is not extensively metabolized, although it is a substrate of CYP3A4, which introduces drug-drug interactions concerns. As adoption and implementation of LEN for treatment and prevention increase, additional guidance on concomitant medications with LEN is needed. Primidone is a barbiturate type anticonvulsant medication and a moderate-to-strong inducer of CYP3A4. A primary metabolite of primidone, phenobarbital, also induces CYP3A. Consequently, the coadministration of LEN and primidone is not recommended due to the potential induction of CYP3A-mediated metabolism and resultant subtherapeutic LEN concentrations. However, the extent to which LEN concentrations may decrease alongside concomitant primidone is unknown. Herein, we describe a 67-year-old male initiating LEN following switch from a boosted darunavir regimen, alongside long-standing treatment with primidone 50 mg daily. Blood samples were collected throughout the first 6-month dosing interval. Plasma LEN concentrations were quantified using a validated liquid chromatography-tandem mass spectrometry analytical method. LEN concentrations remained above four times the protein adjusted 95% effective concentration during the measured time points. The lowest observed concentration was 24.9 ng/mL at Month 1; the highest observed was 58.3 ng/mL at Month 3. The projected 6-month concentration was 40.6 ng/mL. Observed concentrations were generally consistent with concentrations reported in prior studies in the absence of clinically-significant drug-drug interactions. Viral load measures remained undetectable throughout the dosing interval and following subsequent administrations thereafter. This case provides pharmacokinetic rationale for the coadministration of LEN with primidone and may help guide future clinical decision-making.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Devanathan AS, Glowa T, Thompson EM, et al. Lenacapavir initiation with concomitant primidone: A case report with therapeutic drug monitoring. Br J Clin Pharmacol. 2026. PMID: 42836661. doi:10.1002/bcp.70873

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。